Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free PTGX Stock Alerts

Protagonist Therapeutics (PTGX) Short Interest Ratio & Short Volume

Protagonist Therapeutics logo
$105.09 +1.21 (+1.17%)
As of 03:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Protagonist Therapeutics Short Interest Overview

As of April 30, 2026, Protagonist Therapeutics (PTGX) had a short interest of 7.54 million shares sold short, representing 12.37% of the public float. This marks a -10.20% decrease in short interest since the prior report. The short interest ratio (days to cover) is 11.9, meaning it would take 11.9 days of the average trading volume of 761,572 shares to cover all short positions.

Current Short Interest
7,540,996 shares
Previous Short Interest
8,397,278 shares
Change Vs. Previous Month
-10.20%
Dollar Volume Sold Short
$746.33 million
Short Interest Ratio
11.9 Days to Cover
Last Record Date
April 30, 2026
Outstanding Shares
64,311,000 shares
Short Percent of Float
12.37%
Today's Trading Volume
199,483 shares
Average Trading Volume
761,572 shares
Today's Volume Vs. Average
26%
Short Selling Protagonist Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Protagonist Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

PTGX Short Interest Over Time

PTGX Days to Cover Over Time

PTGX Percentage of Float Shorted Over Time

Protagonist Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/30/20267,540,996 shares $746.33 million -10.2%12.4%11.88 $98.97
4/15/20268,397,278 shares $885.41 million -2.7%13.8%11.61 $105.44
3/31/20268,626,880 shares $909.27 million +7.0%14.2%7.64 $105.40
3/13/20268,060,991 shares $744.51 million -1.6%13.3%10.88 $92.36
2/27/20268,192,998 shares $754.41 million -3.0%13.5%16.48 $92.08
2/13/20268,443,732 shares $688.08 million +3.8%14.2%13.31 $81.49
1/30/20268,132,629 shares $665.25 million -2.0%13.7%10.56 $81.80
1/15/20268,297,775 shares $703.24 million +13.8%14.0%8.75 $84.75
12/31/20257,292,034 shares $636.89 million +11.5%12.3%9.51 $87.34
12/15/20256,539,025 shares $619.83 million +11.2%11.0%6.01 $94.79
11/28/20255,883,017 shares $529.32 million +5.4%9.9%7.07 $89.98
11/14/20255,582,326 shares $472.32 million +2.1%9.4%5.85 $84.61
10/31/20255,465,729 shares $429.72 million -13.4%9.2%5.6 $78.62
10/15/20256,310,000 shares $490.16 million -5.0%10.7%5.8 $77.68
9/30/20256,640,000 shares $441.10 million -0.3%N/A7.8 $66.43
9/15/20256,660,000 shares $388.81 million -2.8%N/A8.1 $58.38
8/31/20256,850,000 shares $404.49 million +8.6%11.6%8.2 $59.05
8/15/20256,310,000 shares $353.80 million +9.6%N/A8 $56.07
7/31/20255,760,000 shares $310.23 million -6.8%9.7%7 $53.86
7/15/20256,180,000 shares $341.88 million -8.2%N/A7.1 $55.32
6/30/20256,730,000 shares $371.97 million +13.9%11.4%6.8 $55.27
6/15/20255,910,000 shares $333.15 million +13.4%10.0%5.8 $56.37
5/31/20255,210,000 shares $246.33 million -1.5%9.2%4.4 $47.28
5/15/20255,290,000 shares $234.93 million -13.6%9.4%4.2 $44.41
4/30/20256,120,000 shares $280.42 million +9.9%N/A5 $45.82
4/15/20255,570,000 shares $261.51 million +18.3%9.9%4.8 $46.95
3/31/20254,710,000 shares $227.78 million -8.2%8.4%4.4 $48.36
3/15/20255,130,000 shares $281.02 million +5.3%9.1%5.4 $54.78
2/28/20254,870,000 shares $183.06 million +15.4%8.6%6 $37.59
2/15/20254,220,000 shares $163.19 million +11.4%7.5%6.4 $38.67
1/31/20253,790,000 shares $143.26 million +3.3%N/A5.5 $37.80
1/15/20253,670,000 shares $139.24 million -3.4%N/A5.5 $37.94
12/31/20243,800,000 shares $146.68 million +5.3%N/A5.7 $38.60
12/15/20243,610,000 shares $148.30 million +6.2%N/A5.4 $41.08
11/30/20243,400,000 shares $148.92 million +3.0%N/A5 $43.80
11/15/20243,300,000 shares $135.66 million +0.6%N/A4.9 $41.11
10/31/20243,280,000 shares $150.36 million +9.3%N/A5.5 $45.84
10/15/20243,000,000 shares $142.92 million -14.8%N/A4.6 $47.64
9/30/20243,520,000 shares $158.40 million +9.0%N/A5.2 $45.00
9/15/20243,230,000 shares $151.87 million -1.5%N/A3.4 $47.02
Read this warning immediately (Ad)

Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel

Read Porter Stansberry's full breakdown and protect your wealth now
8/31/20243,280,000 shares $140.68 million +5.8%N/A3.5 $42.89
8/15/20243,100,000 shares $125.83 million +6.9%N/A3.2 $40.59
7/31/20242,900,000 shares $108.58 million -11.0%N/A3.1 $37.44
7/15/20243,260,000 shares $119.81 million +59.8%N/A3.6 $36.75
6/30/20242,040,000 shares $70.69 million -34.6%N/A2.4 $34.65
6/15/20243,120,000 shares $104.18 million -7.7%N/A5.3 $33.39
5/31/20243,380,000 shares $95.15 million -2.6%N/A5.8 $28.15
5/15/20243,470,000 shares $109.20 million -7.0%N/A6.3 $31.47
4/30/20243,730,000 shares $93.66 million +6.0%N/A6.6 $25.11
4/15/20243,520,000 shares $93.56 million +2.3%N/A5.2 $26.58
3/31/20243,440,000 shares $99.52 million +0.6%N/A4.6 $28.93
3/15/20243,420,000 shares $99.11 million +16.3%N/A4.7 $28.98
2/29/20242,940,000 shares $89.32 million +5.8%N/A3.6 $30.38
2/15/20242,780,000 shares $78.48 million +6.5%N/A3.5 $28.23
1/31/20242,610,000 shares $65.28 million +2.4%N/A3.2 $25.01
1/15/20242,550,000 shares $66.05 million +8.5%N/A3.5 $25.90
12/31/20232,350,000 shares $53.89 million -41.0%N/A3.3 $22.93
12/15/20233,980,000 shares $83.86 million +9.3%N/A5.6 $21.07
11/30/20233,640,000 shares $66.28 million -0.3%N/A5.4 $18.21
11/15/20233,650,000 shares $59.46 million -7.4%N/A5.7 $16.29
10/31/20233,940,000 shares $57.29 million +15.5%N/A6 $14.54
10/15/20233,410,000 shares $52.65 million +8.3%N/A5.3 $15.44
9/30/20233,150,000 shares $52.54 million +12.5%N/A4.5 $16.68
9/15/20232,800,000 shares $50.12 million +1.8%N/A3 $17.90
8/31/20232,750,000 shares $54.51 million -9.2%N/A2.8 $19.82
8/15/20233,030,000 shares $56.84 million +2.0%N/A2.8 $18.76
7/31/20232,970,000 shares $57.62 million -10.5%N/A2.7 $19.40
7/15/20233,320,000 shares $70.55 million +4.4%N/A2.8 $21.25
6/30/20233,180,000 shares $87.83 million +18.2%N/A2.7 $27.62
6/15/20232,690,000 shares $77.15 million -12.1%N/A2.5 $28.68
5/31/20233,060,000 shares $79.77 million -15.0%N/A2.5 $26.07
5/15/20233,600,000 shares $93.49 million -3.2%N/A2.2 $25.97
4/30/20233,720,000 shares $84.07 million -14.7%N/A2.2 $22.60
4/15/20234,360,000 shares $81.71 million +0.5%N/A2.5 $18.74
3/31/20234,340,000 shares $99.82 million -16.1%N/A2.6 $23.00
3/15/20235,170,000 shares $124.34 million +88.7%N/A3.2 $24.05
2/28/20232,740,000 shares $44.44 million +5.4%6.3%1.9 $16.22
2/15/20232,600,000 shares $42.43 million +2.0%6.0%2.5 $16.32
1/31/20232,550,000 shares $33.89 million +25.6%5.9%2.7 $13.29
1/15/20232,030,000 shares $24.71 million +14.0%4.7%2.4 $12.17
12/30/20221,780,000 shares $19.42 million -4.3%4.1%2.3 $10.91
12/15/20221,860,000 shares $17.73 million +6.9%4.3%2.4 $9.53
11/30/20221,740,000 shares $13.76 million -4.4%4.0%2.2 $7.91
11/15/20221,820,000 shares $14.63 million -7.6%4.2%2.4 $8.04
10/31/20221,970,000 shares $15.96 million -11.7%4.5%2.5 $8.10
10/15/20222,230,000 shares $17.82 million -8.2%5.1%2.6 $7.99
9/30/20222,430,000 shares $20.48 million -13.5%5.6%2.7 $8.43
9/15/20222,810,000 shares $23.24 million +9.3%6.5%2.8 $8.27
8/31/20222,570,000 shares $22.41 million -11.4%5.9%2.4 $8.72
8/15/20222,900,000 shares $32.86 million -31.6%6.7%2.7 $11.33
Read this warning immediately (Ad)

Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel

Read Porter Stansberry's full breakdown and protect your wealth now
7/31/20224,240,000 shares $42.19 million -13.1%N/A3.5 $9.95
7/15/20224,880,000 shares $46.16 million +2.3%N/A3.5 $9.46
6/30/20224,770,000 shares $37.73 million +18.4%N/A3.4 $7.91
6/15/20224,030,000 shares $30.14 million +18.9%N/A3 $7.48
5/31/20223,390,000 shares $29.70 million +1.5%N/A2.9 $8.76
5/15/20223,340,000 shares $29.43 million +1.5%N/A2.9 $8.81
4/30/20223,290,000 shares $29.91 million +20.5%N/A3.1 $9.09
4/15/20222,730,000 shares $54.46 million -16.3%N/A3.3 $19.95
3/31/20223,260,000 shares $77.20 million -17.5%N/A4.6 $23.68
3/15/20223,950,000 shares $101.99 million -0.8%N/A5.7 $25.82
2/28/20223,980,000 shares $96.63 million -19.1%N/A5.6 $24.28
2/15/20224,920,000 shares $141.35 million +25.5%N/A7.3 $28.73
1/31/20223,920,000 shares $114.82 million +9.5%N/A6.4 $29.29
1/15/20223,580,000 shares $128.74 million +10.2%N/A5.9 $35.96
12/31/20213,250,000 shares $111.15 million +2.2%N/A2.4 $34.20
12/15/20213,180,000 shares $97.12 million +2.6%N/A2.2 $30.54
11/30/20213,100,000 shares $104.22 million -17.6%7.3%1.6 $33.62
11/15/20213,760,000 shares $134.38 million -15.1%8.8%1.9 $35.74
10/29/20214,430,000 shares $138.04 million +18.5%10.5%2.3 $31.16
10/15/20213,740,000 shares $115.83 million +2.8%8.9%2 $30.97
9/30/20213,640,000 shares $64.50 million +27.3%8.7%2.1 $17.72
9/15/20212,860,000 shares $132.90 million -6.5%6.8%3 $46.47
8/31/20213,060,000 shares $148.41 million -4.4%7.3%7.3 $48.50
8/13/20213,200,000 shares $152.61 million +5.6%7.6%7.3 $47.69
7/30/20213,030,000 shares $149.77 million -11.1%7.3%6.9 $49.43
7/15/20213,410,000 shares $150.93 million -1.7%8.3%8.1 $44.26
6/30/20213,470,000 shares $155.73 million -1.4%8.5%8.5 $44.88
6/15/20213,520,000 shares $134.29 million -3.8%8.6%9.3 $38.15
5/28/20213,660,000 shares $128.50 million -6.2%9.7%11.6 $35.11
5/14/20213,900,000 shares $113.10 million +26.2%N/A12.2 $29.00

PTGX Short Interest - Frequently Asked Questions

Short interest is the volume of Protagonist Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 7,540,996 shares of PTGX short. 12.37% of Protagonist Therapeutics' shares are currently sold short. Learn More on Protagonist Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PTGX shares currently have a short interest ratio of 11.9. Learn More on Protagonist Therapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Protagonist Therapeutics: Tudor Investment Corp ET AL, Walleye Trading LLC, and Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.37% of Protagonist Therapeutics' floating shares are currently sold short.

Protagonist Therapeutics saw a drop in short interest in April. As of April 30th, there was short interest totaling 7,540,996 shares, a drop of 10.2% from the previous total of 8,397,278 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

12.37% of Protagonist Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Protagonist Therapeutics: Roivant Sciences Ltd. (4.24%), Moderna, Inc. (16.47%), Viatris Inc. (3.25%), Genmab A/S Sponsored ADR (1.38%), Summit Therapeutics PLC (22.80%), Regencell Bioscience Holdings Limited (0.16%), Ascendis Pharma A/S (7.57%), BridgeBio Pharma, Inc. (14.30%), Dr. Reddy's Laboratories Ltd (1.92%), Elanco Animal Health Incorporated (4.93%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($86.09 billion), Invesco QQQ ($39.89 billion), iShares Russell 2000 ETF ($26.13 billion), Western Digital Corporation ($12.66 billion), Salesforce Inc. ($12.29 billion), Sandisk Corporation ($11.87 billion), SPDR S&P Biotech ETF ($9.82 billion), Lumentum Holdings Inc. ($8.51 billion), iShares 20+ Year Treasury Bond ETF ($7.76 billion), and Bloom Energy Corporation ($7.40 billion). View all of the most shorted stocks.

Short selling PTGX is an investing strategy that aims to generate trading profit from Protagonist Therapeutics as its price is falling. PTGX shares are trading up $0.42 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Protagonist Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PTGX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTGX, twice per month. The most recent reporting period available is April, 30 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like PTGX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:PTGX) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners
One coin wired into Elon's vision
The SpaceX IPO is projected to raise $75 billion in a single day... When that happens, the insiders who cashed...
Crypto 101 Media | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Tengu is coming (prepare for June 16)
A data leak exposed the code name of an AI breakthrough called Project Tengu - and in just six days, it erased...
Chaikin Analytics | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel